Better survival with neoadjuvant dose-dense MVAC regimen in MIBC - Medical Conferences
EAU15 - Poster: Neoadjuvant dose-dense MVAC for muscle invasive bladder cancer; efficacy and safety compared to the traditional MVAC regimen
GETUG on Twitter: "VESPER (NCT01812369) phase III trial in bladder cancer comparing cisplatin-gemcitabine and dose-dense MVAC in perioperative setting. Preliminary results at ASCO GU 2020 https://t.co/kpjFOQLmap" / Twitter
Preoperative Chemotherapy with Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin for Muscle-Invasive Urothelial Ca
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
Educational Centre:Current Clinical Problems in Bladder Cancer
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
The rate of all-grade and grade ≥ 3 adverse events (AEs) for dose-dense... | Download Table
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses -
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - ScienceDirect
Pierre Blanchard, MD on Twitter: "PRACTICE CHANGING @GETUG_Unicancer TRIAL FOR BLADDER CANCER at #ESMO21 Dose dense MVAC improves PFS & OS over Gem-Cisplatin as periop treatment (neoadj 89%; adj 11%) chemo in
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Muskelinvasives Blasenkarzinom: Dosisdichte neoadjuvante Therapie als neuer Standard
Dose-dense MVAC vs gemcitabine and cisplatin tied to better survival in bladder cancer patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin As Perioperative Chemotherapy for Patients With MIBC
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
Approved checkpoint inhibitors in bladder cancer: which drug should be used when? - Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack, 2018
PT0 after NAC: Implications for Bladder Sparing and Prognosis
VESPER - Slideset Download - ESMO 2021 | CCO
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO - ScienceDirect
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). | Semantic
Neoadjuvant Dose-Dense MVAC Demonstrates Superior Survival Outcomes in Bladder Cancer
Randomized phase III trial of dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints -
